Publicity materials
2022/06/02
Release
Megakaryon Corporation initiates first-in-human clinical trial of allogenic human iPSC-derived HLA homozygous platelets (MEG-002).
PDF [PDF:299KB]
2021/10/27
Release
Notice of Management change
PDF [PDF:160KB]
2021/04/26
Release
Megakaryon Corporation announces the completion of 30-day review of Clinical trial notification submitted for human iPS cell-derived HLA homozygous platelets (MEG-002).
PDF [PDF:185KB]
2020/10/27
Release
Notice of Management change
PDF [PDF:162KB]
2020/06/22
Release
Contract for manufacturing of clinical trial formulations
PDF [PDF:190KB]
2020/02/17
Release
Megakaryon Raises Yen 2.8 Billion in Series D Financing
PDF [PDF:196KB]
2020/02/14
News
Megakaryon Corporation along with the partner companies won the Minister of State for Science and Technology Policy Award at the 2nd Japan Open Innovation contest.
PDF [PDF:330KB]
2019/10/25
Release
Notice of Management change
2018/03/08
News
Our Company has been listed on the Forbes USA
2017/12/25
Releases
¥3,700 million in additional funding raised through private placement of new shares.
2017/06/28
News
To be featured at 2017 Japan US Innovation Awards Symposium at Stanford.
PDF [PDF:250KB]
2016/05/01
News
Kyoto Office and Kyoto Lab Expansion.
2016/04/12
News
Our project adopted as a program of AMED(Japan Agency for Medical Research and Development) for Focused on Developing Key Evaluation Technology: Evaluation for Industrialization in the Field of Regenerative Medicine.
2015/11/25
News
Commenced Collaborative Research with Harvard University (Boston Children's Hospital)
2015/08/20
News
Articles about our project published in following websites
webpage https://sangakukan.jp/journal/journal_contents/2015/06/articles/1506-02-2/1506-02-2_article.html
webpage http://www.keguanjp.com/kgjp_jingji/kgjp_jj_cxg/pt20150730135747.html
2015/03/20
Releases
Capital increased through private placement of new shares(Amount raised: ¥2,540 million)
PDF [PDF:500KB]
2015/03/19
Releases
Company officially recognized as a Designated Core Business within the Kansai National Strategic Special Zone
PDF [PDF:540KB]
pagetop